Analysts Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Target Price at $133.13

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been assigned a consensus rating of “Moderate Buy” from the eighteen analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $133.1333.

A number of equities analysts recently issued reports on BNTX shares. Raymond James Financial reissued an “outperform” rating on shares of BioNTech in a report on Tuesday, March 10th. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a report on Wednesday, March 11th. Leerink Partners lowered BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective for the company. in a report on Monday, February 2nd. HC Wainwright decreased their price objective on BioNTech from $140.00 to $130.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of BioNTech in a report on Wednesday, March 11th.

BioNTech Stock Up 1.3%

Shares of BioNTech stock opened at $96.70 on Friday. The company has a current ratio of 7.54, a quick ratio of 7.49 and a debt-to-equity ratio of 0.01. The business’s 50 day simple moving average is $98.57 and its 200-day simple moving average is $101.04. The stock has a market capitalization of $24.45 billion, a price-to-earnings ratio of -18.45 and a beta of 1.58. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%.The company had revenue of $1.06 billion for the quarter. Equities research analysts forecast that BioNTech will post -3.88 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hsbc Holdings PLC bought a new position in BioNTech in the 4th quarter worth approximately $4,969,000. Rockefeller Capital Management L.P. grew its holdings in BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after buying an additional 1,423 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in BioNTech by 1,012.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after buying an additional 506 shares in the last quarter. Sankala Group LLC bought a new position in BioNTech in the 4th quarter worth approximately $248,000. Finally, Virtu Financial LLC boosted its stake in BioNTech by 163.9% during the 4th quarter. Virtu Financial LLC now owns 11,244 shares of the company’s stock valued at $1,070,000 after purchasing an additional 6,984 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.